(Received for publication, August 17, 1995; and in revised form, December 19, 1995)
From the
The Kv3.1 potassium channel is expressed in neurons that generate trains of high frequency action potentials in response to synaptic inputs. To understand the mechanisms underlying the regulation and restricted expression pattern of the Kv3.1 gene, we have cloned and characterized its promoter. We first isolated a 5.3-kilobase pair fragment of the Kv3.1 5`-flanking region. When linked to the chloramphenicol acetyltransferase reporter gene, this fragment was found to be active in the undifferentiated PC12 cell line, a neuron-like cell line, but not in a fibroblast cell line. By carrying out a series of deletion analyses in undifferentiated PC12 cells, we have localized the essential promoter region to a highly GC-rich region containing four Sp-1 binding sites. Similar deletion analysis in NIH3T3 cells suggests that multiple silencing elements and enhancing element(s) are involved in the cell type-specific expression of this gene. Further regulatory elements, including one cyclic AMP/calcium response element (CRE) and one Ap-1 element were found in the upstream region of the promoter. Using a stable undifferentiated PC12 cell line transfected with the Kv3.1 5`-flanking region, we determined that promoter activity is enhanced by a cAMP analog and a calcium ionophore. Deletion of the CRE-like element at position -252 eliminated the enhancement of promoter activity by cAMP, and mobility shift assays confirmed that the Kv3.1 CRE sequence binds both a nuclear factor in undifferentiated PC12 cells and recombinant CRE binding protein. Our results suggest that the transcription of the Kv3.1 channel may be regulated by neurotransmitters that elevate cAMP levels in neurons.
The Kv3.1 gene encodes a mammalian voltage-dependent potassium
channel that is related to the Drosophila Shaw gene(1, 2) . In contrast to many other potassium
channels that are expressed in a variety of tissues, the Kv3.1 channel
appears to be expressed only in brain and in a subpopulation of T
lymphocytes(1, 3, 4) . In situ hybridization and immunocytochemistry have shown that within the
nervous system, the Kv3.1 K channel is found only in a
subset of
neurons(4, 5, 6, 7, 8) . In
particular, it is expressed at particularly high levels in neurons that
are capable of firing action potentials at high frequencies with little
or no adaptation during maintained trains of synaptic
inputs(5) . Examples of such cells include neurons in auditory
brainstem that phase-lock their action potentials to stimulus
frequencies of up to several kHz (see (9, 10, 11) ) and hippocampal and cortical
interneurons, which are capable of generating trains of action
potentials at several hundred Hz (see (12) and (13) ).
The biophysical characteristics of the Kv3.1 channel also differ
from those of many other voltage-dependent potassium channels. For
example, when the Kv3.1 channel is expressed in a heterologous
expression system such as Xenopus oocytes or a mammalian cell
line, it activates at relatively positive potentials and has very rapid
deactivation kinetics when compared with other members of the Shaker superfamily of
channels(1, 14, 15, 16) . Computer
simulation studies suggest that a channel with these characteristics
minimizes the relative refractory period that follows individual action
potentials, and that changes in the amplitude of such a current alter
the ability of a neuron to follow high frequency synaptic
inputs(17) . The precise factors that determine the level of
expression of Kv3.1 channels in neurons are not known. However, it has
been shown that the levels of the Kv3.1 message are developmentally
regulated(4, 5) . Furthermore, experiments in cell
lines indicate that Kv3.1 transcription may be regulated by
Ca, cAMP, and growth factors(18) . In the
present study, we have identified and characterized the promoter region
for the Kv3.1 gene to investigate the mechanisms that regulate
transcription of the Kv3.1 channel.
Constructs pCATE1213 and pCAT1213, which were used for stable transfections, were generated using Exonuclease III (Promega) to delete sequence from the 5`-end of pKS 6000. A plasmid with a deletion of approximately 4 kb at its 5`-end was designated as pKS 2000. Its insert was then subcloned into both the pCATE vector to generate pCATE1213 and the pCAT-basic vector to generate pCAT1213. Similarly, pCAT+22 was constructed by deleting pKS 2000 at its 5`-end using Exonuclease III.
Other clones were constructed by using convenient restriction enzyme sites. pCAT528 and pCAT266 were constructed from pCAT1213. PCAT528 was constructed from a PstI and XhoI fragment of pCAT1213, which was blunt end-treated with Klenow enzyme before ligation. PCAT266 was constructed from the PstI(blunt-ended)-SmaI fragment of pCAT1213. pCAT226 and pCAT71 were generated from pKS 1000. For pCAT226, the SpeI(blunt-ended)-SalI fragment was inserted into the pCAT-basic vector cut with PstI (blunt-ended) and SalI. Likewise, the NarI(blunt-ended)-SalI fragment was inserted into the pCAT-basic vector cut with PstI (blunt-ended) and SalI to create pCAT71. PCATE71 was generated by inserting the NarI(blunt-ended)-SalI fragment into the pCATE vector.
Plasmid DNAs purified by CsCl
banding were transfected using LipofectAmine (Life Technologies, Inc.).
5 µg of the CAT constructs and 5 µg of the pREP-lacZ
(Invitrogen), a plasmid containing the -galactosidase gene driven
by the Rous sarcoma virus promoter, were cotransfected into the cells.
2 days after the transfection, the cells were harvested for analysis.
The cell lysates were obtained by three cycles of freeze-thawing. The
efficiencies of transfections were normalized using the activity of
-galactosidase in cell lysates as described by Sambrook et
al.(20) . CAT assays were performed as described by Gorman et al.(21) . The conversion rates from chloramphenicol
to acetylated forms were quantified using a liquid scintillation
counter.
The regulation of the Kv3.1 promoter by different factors was studied in stable cell lines transfected with pCATE1213 and pCAT1213. In some experiments, transfected cells were incubated for 24 h with 1 mM dibutyryl cAMP and/or 5 µM ionomycin before harvesting and preparation of cell lysates. The amount of protein used in each assay was determined (22) and used for normalization of results.
The response to cAMP was also tested in transiently transfected cells. In these experiments, cells grown in a 60-mm dish were transfected and split 24 h later into four 35-mm dishes. The cells were allowed to attach for several hours and then treated with 1 mM dibutyryl cAMP for 24 h before harvesting and determination of CAT activity.
In
the RNase protection assay to determine transcription start sites, a
[P]CTP-labeled antisense RNA probe was
transcribed using T7 polymerase from pKS 1000 linearized with BamHI. The resulting probe is complementary to the 158 bp of
the published 5` region and extends 286 bp upstream in the genomic
clone. Subsequent procedure was similar to that described by Chamberlin
and Ryan(24) . Briefly, an excess of the
P-labeled
probe was hybridized with 10 µg of total RNA from rat cerebellum or
tRNA in 80% formamide at 46 °C. The single-stranded RNAs were then
digested with 0.5 µg/ml RNase A and 6.5 µg/ml RNase T1. The
protected fragments were run on denaturing polyacrylamide gels and
autoradiographed. RNase protection assays were also conducted to
analyze the regulation of Kv3.1 mRNA by 1 mM 8-bromo-cAMP.
Total RNA from PC12 cells treated for 24-48 h by 1 mM 8-bromo-cAMP and control cells were hybridized with Kv3.1-specific
riboprobe as described previously(5) . Antisense probe from the
glyceraldhyde-3-phosphate dehydrogenase gene (Ambion, TX) was used as
an internal standard to normalize the amount of total RNA used.
Protected bands shown on autoradiography were quantified using an
IS-1000 Digital Imaging system (Alpha Innotech Corporation, CA).
For
mobility shift assays, a double-stranded oligonucleotide probe
(end-labeled with [-
P]ATP) was made
corresponding to the region surrounding the putative CRE site
(GCGAGCCCAGACGTCGCTGGGAGC). An oligonucleotide in which the CRE-like
sites were mutated, CRM, was also used in the assay as noncompetitor
(GCGAGCCCAGTTGTCGCTGGGAGC). In addition, an oligonucleotide probe with
the somatostatin CRE core region(26) ,
AGAGATTGCCTGACGTCAGAGAGCTAG, was used as a positive control. The
oligonucleotide probes (0.5 ng) were incubated with 2 µg of the
extract or 1-2 µg of the recombinant CREB-1 protein and 0.5
µg of poly(dI-dC) in a total volume of 10 µl containing 4%
glycerol, 1 mM MgCl
, 0.5 mM EDTA, 0.5
mM dithiothreitol, 50 mM NaCl, 10 mM Tris-HCl, pH 7.5, as described in Ausubel et
al.(27) . The reaction mixtures were incubated at room
temperature for 20 min. Cold double-stranded oligonucleotides in 10-
and 100-fold excess were added in the preincubation step (before adding
the probe) and used as competitors to show the specificity of the
binding. The reaction mixtures were then run on a 4% nondenaturing
acrylamide gel at 150 V for more than 3 h, and the products were
detected by autoradiography.
Figure 1:
Rat Kv3.1 genomic DNA containing the 5`
noncoding region and 5`-flanking region. A schematic diagram of the
Kv3.1 genomic clone, containing approximately 15 kb of the 5`-flanking
region. The indicated restriction sites are as follows: S, SalI; X, XhoI; H, HindIII; N, NotI; B, BamHI. The thick
black bar within the boxed region represents 5`-noncoding
region that overlaps with the probe derived from the Kv3.1 cDNA clone
(Luneau et al.(1) ). The stippled area corresponds to the sequence shown in Fig. 3. 09,
04, and
16 represent
overlapping phage clones isolated from a rat genomic
library.
Figure 3: Nucleotide sequence of the rat Kv3.1 promoter region. Numbers represent nucleotide position relative to the most 3` of the major start sites (+1). The other major transcription start site is also labeled with an asterisk. One CRE-like, one Ap-1 consensus element, and five consensus Sp-1 sites are underlined. The junctions of the deletion constructs shown in Fig. 4are also labeled and underlined.
Figure 4:
Functional analysis of Kv3.1 promoter
activity in undifferentiated PC12 cells and in NIH3T3 cells. Left, the extent of the 5` deletions of the promoter region in
different constructs are represented qualitatively by the lengths of
the thin lines, which are coupled to the CAT reporter gene at
the right end of each construct. The approximate positions of Ap-1,
CRE, and Sp-1 sites are indicated in the constructs. Right,
CAT activities of the different deletion constructs are expressed
relative to the vector pCATSV40, which contains the SV40 promoter. All
of the values are normalized to the activities of -galactosidase
gene, which was cotransfected with CAT constructs. pCAT+22 was
only transfected into undifferentiatd PC12 cells, not into NIH3T3
cells. Results represent the mean relative activities ± S.E.
from three to seven independent experiments with two different plasmid
preparations.
Figure 2: Identification of the transcription start sites of the Kv3.1 gene. A, a primer extension assay. In the right lane (CB), 10 µg of cerebellar total RNA was used as a template in the assay. The primer is located at a position 38-57 bp downstream of the published 5`-end(1) . B, RNase protection assay. A labeled riboprobe corresponding to the region spanning the putative transcription start sites was hybridized with 10 µg of total RNA isolated from rat cerebellum (CB) or tRNA and then digested with RNase A and RNase T1 for 30 min (CB lane, left) or 60 min (CB lane, right). No bands were seen with tRNA. A sequence ladder of known sequence was used as a size marker (left four lanes).
To verify the heterogeneous 5`-end of the Kv3.1 mRNA molecule, we also analyzed rat cerebellar RNA by RNase protection assays (Fig. 2B). A 458-base RNA probe, designed to be complementary to a genomic fragment spanning the putative transcription start sites, was hybridized with total RNA isolated from rat cerebellum or with tRNA. As shown in Fig. 2B, protected bands were only observed with RNA isolated from the cerebellum, which normally expresses the Kv3.1 channel. The length of the protected bands in the RNase assay indicates the distance from the start of the mRNA to the 3`-end of the probe. Because the antisense RNA probe extends 101 bp to the 3`-end of the sequence used in the primer extension analysis, the sizes of the two major bands (166 and 175 bp) were in perfect agreement with the sizes of the bands detected by primer extension (65 and 74 bp). As in the primer extension experiments, there were also several minor sites lying in the upstream region of the two major cap sites. We found it difficult to determine the exact positions of these minor sites, which did not appear to agree exactly with those detected by primer extension analysis. It is therefore not clear whether these minor sites represent real, alternate transcription start sites.
Together, these results demonstrate the existence of two principal transcriptional initiation sites in the Kv3.1 gene, appearing 8 and 17 bp from the 5`-end of the cDNA clone. Both are labeled with asterisks in Fig. 3, which shows the sequence of the upstream region of the Kv3.1 gene. The position of the more 3` of the two start sites is assigned as +1.
In PC12 cells, in the absence of the SV40 enhancer, CAT expression driven by the 5.3-kb fragment was 2-3 times higher than that produced by the SV40 promoter (Table 1). In contrast, this fragment exhibited little if any activity compared with the SV40 promoter in NIH3T3 fibroblasts, suggesting that the tissue-specific expression of the Kv3.1 gene may, at least in part, be dependent on the upstream regulatory region of the Kv3.1 gene. In control experiments, constructs that comprised the vector without the 5.3-kb fragment or that contained the 5.3-kb fragment in 3` to 5` orientation, generated little to no CAT activity (Table 1). Interestingly, in the presence of SV40 enhancer, a nonspecific enhancer, the activity of the 5.3-kb 5`-fragment in NIH3T3 cells was increased and the cell type specificity of this upstream regulatory region was quenched (Table 1).
A diagram of the deletion constructs with the CAT reporter gene is shown in Fig. 4. In PC12 cells, lysates of cells transfected with the constructs pCAT1213 and pCAT528 showed little change in CAT activity compared with that of pCAT5300. As the upstream region was further deleted, however, transcriptional activity increased. Maximum activity occurred when only 266 bp upstream of the transcription initiation site were present. This result suggests that a negative element or elements may exist in the upstream region between -528 and -266.
Further deletion to produce construct pCAT226 did not produce a substantial decrease in CAT activity, indicating that deletion of the Sp-1 element at position -234 to -229 does not decrease promoter activity significantly. However, removal of the region from -226 to -71, which contains the other four Sp-1 elements, resulted in an 80% decrease in CAT activity. Thus, the major positive elements for the Kv3.1 promoter reside within this region. As also shown in Fig. 4, when the Kv3.1 transcriptional start sites are deleted (pCAT+22), promoter activity is almost completely abolished, indicating that the 5`-noncoding region of the Kv3.1 gene does not contain promoter activity.
Similar deletion analyses were also conducted in NIH3T3 cells (Fig. 4). We found that all the constructs with 5` deletions showed much lower CAT activities in NIH3T3 cells than those in PC12 cells (Fig. 4). When the 5.3-kb fragment was deleted to 1213 bp, CAT activity increased. Deletion from -1213 to -528 also resulted in an about 3-fold increase of CAT activity, suggesting that multiple silencing element(s) in the 5`-flanking region are involved in controlling cell type-specific expression. Interestingly, further deletion from -528 to -266 and -226 resulted in a slight decrease in CAT activity. The promoter activities of pCAT266 and pCAT226 are far less active in NIH3T3 cells than in PC12 cells, suggesting that enhancing elements in this region are selectively active in undifferentiated PC12 cells. More detailed analysis will be necessary to map the cell type-specific enhancing elements within the region -226 bp to -71bp.
Figure 5: Effect of cAMP and ionomycin on the Kv3.1 promoter in a stable cell line transfected with pCATE1213. CAT activity in cells treated for 24 h with 1 mM dibutyryl-cAMP, 5 µM ionomycin or both is presented relative to that in control untreated cells (control). An equivalent amount of protein was used in both experimental and control assays. The results shown the mean relative activities ± S.E. of four to six experiments in two to three independent preparation of cells.
To determine if the CRE-like element at -252 participates in the cAMP response of the Kv3.1 promoter, we carried out transient transfections using the series deletion constructs. Fig. 6shows that promoter activity was increased by a 24-h treatment with 1 mM dibutyryl cAMP in cells transfected with constructs containing the CRE-like element (pCAT1213, pCAT528, and pCAT266), but not in cells transfected with pCAT226, in which the CRE-like element is deleted. These data suggests that the region from -266 to -226 surrounding the CRE-like element at position -252 is crucial for the cAMP response of the Kv3.1 promoter.
Figure 6: The effects of dibutyryl cAMP on the Kv3.1 promoter in transient transfections using deleted constructs. Histograms show the change in CAT activity after treatment with 1 mM dibutyryl cAMP for 24 h, relative to untreated cells. Constructs pCAT1213, pCAT528, and pCAT266 all contain the CRE-like element (at -252), while construct pCAT226 does not contain this element. The minimal black bars represent the control (zero change). As described under ``Experimental Procedures,'' the same amount of protein was used to measure CAT activity before and after dibutyryl cAMP treatment. The data shown represent four independent experiments carried out in duplicate.
Figure 7: Mobility shift assay showing binding of nuclear factors in PC12 cells and purified CREB protein to the putative CRE element. A, lane 1, no nuclear extract; lane 2, somatostatin CRE with nuclear extract from PC12 cells; lane 3, somatostatin CRE with nuclear extract and cold competitor oligonucleotide; lane 4, Kv3.1 CRE with nuclear extract; lane 5, Kv3.1 CRE with cold competitor oligonucleotide in the presence of nuclear extract from PC12 cells. B, lane 1, no nuclear extract from PC12 cells; lane 2, Kv3.1 CRE oligonucleotide with nuclear extract from PC12 cells; lanes 3 and 4, Kv3.1 CRE oligonucleotide with 10-fold and 100-fold molar excess of cold competitor respectively; lane 5, Kv3.1 CRE oligonucleotide with 10-fold excess of cold somatostatin CRE. C, lane 1, no purified CREB-bzip protein; lane 2, Kv3.1 CRE oligonucleotide with 1 µg of CREB-bzip protein; lane 3, Kv3.1 CRE oligonucleotide with 2 µg of CREB-bzip protein; lanes 4 and 5, Kv3.1 CRE oligonucleotide with 100- and 10-fold excess of cold competitor; lane 6, Kv3.1 CRE with 100-fold excess of cold mutant noncompetitor (CRM), in which two consensus nucleotides in the Kv3.1 CRE were mutated.
To exclude the
possibility that the SV40 enhancer, which is incorporated in the
pCATE1213 vector (see ``Experimental Procedures''),
contributes to the effects of ionomycin effects, we conducted
experiments using pCATE71, which also contains SV40 enhancer but lacks
putative transcriptional factor binding elements. We found that the CAT
activities in cells transfected with pCATE71 were not up-regulated by 5
µM ionomycin (-5.7% ± 0.061, n = 4). These data suggest that the effects of cAMP and
Ca are mediated directly by the Kv3.1 promoter region
from -1213 bp to -71 bp.
The Shaw-type K channel, Kv3.1, is expressed
primarily in
neurons(4, 5, 6, 7, 8) ,
and levels of Kv3.1 mRNA can be altered by seizures(18) , as
well as by second messengers(18) . To understand the mechanisms
underlying transcriptional control of the Kv3.1 gene, we have cloned
the promoter region of the Kv3.1 K
channel gene. We
find that the Kv3.1 gene contains two principal transcription start
sites and that the proximal promoter region is extremely GC-rich. The
essential promoter activity of the Kv3.1 gene appears to reside in the
region 226 bp upstream of the start sites.
When 5.3 kb of the 5`-flanking region was transfected into undifferentiated PC12 cells, a neuron-like cell line, it produced high transcriptional activity, about 2-3-fold greater than that of the SV40 promoter. In contrast, this fragment was essentially inactive in NIH3T3 fibroblast cells, indicating that the 5` regulatory region plays a crucial role in the tissue-specific expression of this gene. Similar neuronal-restrictive promoter activity has been previously demonstrated for the neuron-specific rat brain type II sodium channel(30) . Within this region, a silencing element was found to be responsible for restricting the expression of this gene to neurons(31) . This neural restrictive silencing element has also been shown to be present in other neuronal genes, like the SCG10 gene (32, 33) and the human synapsin I gene(34) . Interestingly, we have found an element in the Kv3.1 5`-flanking region from -743 to -717 bp bearing 75% identity to the NRSE in the SCG10 gene. As we deleted the Kv3.1 5`-flanking region from -1213 to -528, promoter activity increased, suggesting this NRSE-like element may also play a silencing role here, although more detailed study will be needed to confirm this hypothesis.
A CRE-like
element was found at position -252, 5` to the five putative Sp-1
binding sites. This element is known to mediate the response of
transcription rate to an elevated level of cAMP through CREB. When
phosphorylated by either the cAMP-dependent protein kinase or by a
calcium/calmodulin-dependent protein kinase, the CREB protein binds to
CRE elements enhancing transcription. Further upstream of the CRE-like
element, there exist two consensus Ap-1 elements, which may be
activated by products of immediate early genes. Previous studies have
shown that, besides being regulated by seizure activity(18) ,
the expression levels of the Kv3.1 gene can also be regulated by
extrinsic factors. Studies in the AtT20 cell line have shown that basic
fibroblast growth factor, Ca, depolarization, and
cAMP can regulate the level of Kv3.1 transcripts (18) . In
undifferentiated PC12 cells, we have also shown that cAMP can
up-regulate the level of Kv3.1 transcripts. Our findings that cAMP and
Ca
can also enhance Kv3.1 promoter activity suggest
that the regulatory elements in the Kv3.1 gene may be responsible for
regulating Kv3.1 expression. In particular, our studies strongly
suggest that the CRE-like element at -252 mediates the response
of the Kv3.1 gene to elevations of cyclic AMP levels, since we found
that deletion of the CRE-like element eliminated the response of the
promoter to the cAMP analog. Moreover, an oligonucleotide with the
Kv3.1 CRE sequence binds a nuclear protein to generate a band that
matches that obtained with a somatostatin CRE oligonucleotide, which is
known to bind the CREB protein. Using recombinant CREB protein, we have
further demonstrated that the protein that binds to the Kv3.1 CRE
oligonucleotide is probably CREB itself or a closely related protein.
Both in situ hybridization and immunocytochemistry studies have indicated that the Kv3.1 gene is highly enriched in neurons along auditory pathways, which are capable of firing action potentials at high frequencies(5, 7, 8) . It has been suggested that the presence of a channel with the biophysical characteristics of the Kv3.1 channel allows neurons to generate trains of action potentials that follow high frequency synaptic stimulation with little adaptation(16, 17) , and in the case of neurons in auditory brainstem nuclei, aids in the precise temporal locking of the phase of action potentials to the phase of auditory inputs(17) . The finding that the activity of the Kv3.1 promoter is strongly enhanced by a cAMP analog suggests that neurotransmitters or hormones that elevate cAMP levels may produce changes in the excitability of neurons that express this channel.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBank(TM)/EMBL Data Bank with accession number(s) U44682[GenBank].